Homemigraine

  • Galcanezumab reduces Migraine days for patients failing on other therapies, highlights new subgroup analysis

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • AOBiome initiates Ph 2 trial for episodic migraine

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Strong clinical data with single dose rimegepant in acute treatment of migraine announced by Biohaven

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Promius to present data from Migraine MAST study at AAN 2018

    • April 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments

    MAST seeks to shed light on the current state of migraine symptom characteristics and illustrate the state of migraine treatment.

    read more

  • Biohaven to present additional Phase 3 Rimegepant Data at AAN 2018

    • April 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Alder to present Phase 3 Eptinezumab results at AAN 2018

    • April 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Teva to Present New Data Across Multiple NS Therapeutic Areas at AAN

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Migraine CGRP drugs assessed for Clinical effectiveness & Economic impacts by recent ICER report

    • April 14, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • CRLs, leading to fremanezumab launch delay in Migraine, acknowledged by Celltrion

    • April 10, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Migraine associated with Increased Heart stroke risk, says recent analysis

    • April 6, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more